chartexchange

ADMP
Adamis Pharmaceuticals Corporation
stockNASDAQ

InactiveSep 7, 2023
0.775063USD+0.854%(+0.006563)119,837
Loading…
Loading…
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Dennis Carlo
HQ
San Diego, California, USA
May 22, 2023 · 1-for-70 (reverse)
ADMP Profile

adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division's focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a

ADMP Performance
PeriodPriceDateChange